WORLD PEPTIDEFOUNDATION

Where is Ipamorelin being studied?

Find registered human studies, phases, products, recruitment status and reported research locations around the world. Registry search matches are separate from this profile’s reviewed evidence.

Find studies for Ipamorelin →Worldwide registry directory
Search this profile’s alternative names

Check the intervention identity in each registry record; aliases and combination products can produce broader matches.

Scientific intelligence record

Experience 2.0

Growth-hormone secretagogue

Ipamorelin

Also known as: Ipamorelin acetate, NNC 26-0161

Ipamorelin is a synthetic pentapeptide growth-hormone secretagogue that activates the ghrelin receptor (GHSR1a). It was designed to stimulate pulsatile growth-hormone release with less ACTH or cortisol stimulation than some earlier secretagogues.

Record status

Traceability partial

Last meaningful update: 9/8/2026

Evidence searched through:
Not recorded
Assessment updated:
9/8/2026
Documented human review:
No documented human review recorded
Automated scientific assessment:
9/8/2026
AI source check:
None recorded

Published source links and profile text pass separate gates. Only a documented human review is labelled as human review; an automated scientific assessment applies deterministic checks, and an AI source check confirms only that a source exists and matches its identifiers. A source count alone does not establish a review.

Evidence coverage has three distinct layers. The corpus count is a transparent screening inventory, the featured set contains study-level tiering and interpretation, and the published-source count contains records promoted through the institutional publication workflow. Source validation, editorial publication, and scientific appraisal are separate decisions; these numbers must not be merged.

Ranked research corpus

63

Categorized publications with provisional ranking; scientific review remains separate.

Featured tiered studies

0

Cornerstone publications with study-level interpretation, limitations, and tier disclosure.

Research domains

5

Clinical and scientific questions synthesized independently across the evidence atlas.

Published source records

25

Database records promoted through the governed publication workflow—not the corpus total.

Corpus generated 2026-09-18. Counts remain separately labeled so screening is not represented as completed review.

Human experience · separate evidence stream

No community pattern is displayed yet

Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.

Observation is valuable human context. It is not evidence of causation, efficacy, or safety.

Public display gate

n ≥ 20 eligible observations

Exact progress remains private before the threshold.

Contribute an observationArchive details

Intelligence snapshot

The state of the record

A compact view of what is represented, what remains unresolved, and how completely the record can be traced.

Ranked research corpus

63

Categorized screening records; proposed rankings remain pending human appraisal.

Featured tiered studies

0

Cornerstone studies with published study-level interpretation and tier disclosure.

Research domains

5

Independent evidence dossiers covering the major research questions.

Published source records

25

Source records published through the governed workflow; this count does not certify scientific conclusions.

Contradictions

0

Conflicting evidence relationships that remain visible.

Research gaps

1

Questions the current record identifies as unresolved.

Connected media

0

Media records explicitly linked to this scientific record.

What we know

Evidence, claims, and boundaries

The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.

Reconciled domain conclusions

5 published domain syntheses connected to 0 featured studies

Ipamorelin no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded synthesis, confidence level, evidence context, limitations, geographic applicability, regulatory interpretation, and research gaps. Publication of these syntheses is separate from the scientific review status shown above.

Inspect the reconciled evidence atlas
Inspect the published evidence record25 governed records · titles, provenance, and original-source linksOpen records ↓
1998Phase 1–2 human evidence
Evidence strength B · 70/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
60/100
Directness
88/100
Population relevance
65/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption.

Following i.v. bolus injection, plasma concentrations of the peptides declined biexponentially. Ipamorelin differed markedly from the other peptides investigated, demonstrating a systemic plasma clearance 5-fold lower than that of GHRP-6. Ipamorelin was mainly excre …

Authors
Johansen PB, Hansen KT, Andersen JV, Johansen NL.
Source
peer_reviewed_research
DOI
10.1080/004982598238976
PubMed
9879640
Open original source
2014Phase 1–2 human evidence
Evidence strength B · 74/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
68/100
Directness
88/100
Population relevance
78/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.

Overall incidence of any treatment-emergent adverse events was 87.5 % in the ipamorelin group and 94.8 % in placebo group. Median time to first tolerated meal was 25.3 and 32.6 h in the ipamorelin and placebo groups, respectively (p = 0.15). LIMITATIONS: This proof …

Authors
Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group.
Source
peer_reviewed_research
DOI
10.1007/s00384-014-2030-8
PubMed
25331030
Open original source
1999Phase 1–2 human evidence
Evidence strength B · 70/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
60/100
Directness
88/100
Population relevance
65/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.

The ipamorelin-GH concentration relationship was characterized using an indirect response model and population fitting. ...CONCLUSIONS: The proposed PK/PD model provides a useful characterization of ipamorelin disposition and GH responses across a range of doses....

Authors
Gobburu JV, Agersø H, Jusko WJ, Ynddal L.
Source
peer_reviewed_research
DOI
10.1023/a:1018955126402
PubMed
10496658
Open original source
2026Phase 1–2 human evidence
Evidence strength B · 76/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
68/100
Directness
88/100
Population relevance
78/100
Reporting quality
68/100
Replication
72/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.

Search terms included "peptide therapeutics," "aging," "gerontology," "healthspan," combined with specific peptide names (tirzepatide, epitalon, GHK-Cu, BPC-157, TB-500, Semax, CJC-1295, ipamorelin, bremelanotide). Peer-reviewed articles, clinical trials, regulatory docume …

Authors
Mavrych V, Shypilova I, Bolgova O.
Source
peer_reviewed_research
DOI
10.3389/fragi.2026.1790247
PubMed
42021992
Open original source
2026Phase 1–2 human evidence
Evidence strength C · 63/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
68/100
Directness
45/100
Population relevance
78/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

Our objective is to present the pharmacological mechanisms, safety profiles, and regulatory status of prominent approved and unapproved peptides marketed direct to patients, including AOD-9604 (anti-obesity drug 9604), BPC-157 (body protection compound 157), CJC-1295, FS-344 (fol …

Authors
Mendias CL, Awan TM.
Source
peer_reviewed_research
DOI
10.1007/s40279-026-02437-0
PubMed
41966639
Open original source
2009Animal research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
46/100
Directness
88/100
Population relevance
25/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats.

OBJECTIVES: Growth hormone (GH) reduces the catabolic side effects of steroid treatment via effects on the amino-nitrogen metabolism. Ipamorelin is a synthetic peptide with GH releasing properties. We wished to study the metabolic effects of Ipamorelin and GH on sel …

Authors
Aagaard NK, Grøfte T, Greisen J, Malmlöf K, Johansen PB, Grønbaek H, Ørskov H, Tygstrup N, Vilstrup H.
Source
peer_reviewed_research
DOI
10.1016/j.ghir.2009.01.001
PubMed
19231263
Open original source
2001Animal research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
46/100
Directness
88/100
Population relevance
25/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues.

In +/lit and lit/lit mice ipamorelin induced a small (15%) increase in body weight by 2 weeks, that was not further augmented by 9 weeks. GH treatment markedly enhanced body weight in both groups. Ipamorelin also increased fat pad weights relative to body weight in …

Authors
Lall S, Tung LY, Ohlsson C, Jansson JO, Dickson SL.
Source
peer_reviewed_research
DOI
10.1006/bbrc.2000.4065
PubMed
11162489
Open original source
2002Animal research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
46/100
Directness
88/100
Population relevance
25/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro.

In the Ipamorelin group alone, in vitro treatment with Ipamorelin (10(-8) M), or GHRP 6 (10(-8) M), or GHRH (10(-8) M) for 4 hours, increased the percentage of somatotroph cells, without modifying the ratio of strongly/weakly immunostained GH cells. Basal intracellu …

Authors
Jiménez-Reina L, Cañete R, de la Torre MJ, Bernal G.
Source
peer_reviewed_research
DOI
10.14670/HH-17.707
PubMed
12168778
Open original source
1999Animal research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
46/100
Directness
88/100
Population relevance
25/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.

The responsiveness of the pituitary to a provocative i.v. dose of ipamorelin or GHRH showed that the plasma GH response was marginally reduced (P<0.03) after ipamorelin, but unchanged after GHRH. The pituitary GH content was unchanged by ipamorelin treatme …

Authors
Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H.
Source
peer_reviewed_research
DOI
10.1054/ghir.1999.9998
PubMed
10373343
Open original source
2001Animal research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
46/100
Directness
88/100
Population relevance
25/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.

The ability of the growth hormone secretagogue (GHS) Ipamorelin to counteract the catabolic effects of glucocorticoid (GC) on skeletal muscles and bone was investigated in vivo in an adult rat model. Groups of 8-month-old female rats were injected subcutaneously for 3 mont …

Authors
Andersen NB, Malmlöf K, Johansen PB, Andreassen TT, Ørtoft G, Oxlund H.
Source
peer_reviewed_research
DOI
10.1054/ghir.2001.0239
PubMed
11735244
Open original source
2026Laboratory research
Evidence strength C · 63/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
72/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Peptide Supplements and Their Therapeutic Applications in Sports Medicine.

PURPOSE: To summarize existing peer-reviewed data on 6 emerging peptides (BPC-157, thymosin beta-4 or TB-500, CJC-1295, MK-677, ipamorelin, and GHK-Cu [copper peptide]) for musculoskeletal recovery and enhancement in animal and human models. ...METHODS: Three independent r …

Authors
Tewari K, Liu TP, Im C, Hamad C, Petrigliano F, Cheung EC, Kremen TJ Jr.
Source
peer_reviewed_research
DOI
10.1177/03635465261464420
PubMed
42578445
Open original source
1998Laboratory research
Evidence strength C · 58/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
18/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Ipamorelin, the first selective growth hormone secretagogue.

The development and pharmacology of a new potent growth hormone (GH) secretagogue, ipamorelin, is described. Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2), which displays high GH releasing potency and efficacy in vitro and in vivo. ...The specificity …

Authors
Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH.
Source
peer_reviewed_research
DOI
10.1530/eje.0.1390552
PubMed
9849822
Open original source
2026Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

Key peptides evaluated included BPC-157, TB-4, TB-500, CJC-1295 + ipamorelin, tesamorelin, and GHK-Cu. RESULTS: BPC-157 demonstrated potential benefits in tendon and muscle repair, but these findings are largely unvalidated in human trials. ...TB-4 and its derivative TB-50 …

Authors
Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF, Gamradt SC, Weber AE.
Source
peer_reviewed_research
DOI
10.1177/03635465251357593
PubMed
41476424
Open original source
2026Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu promote angiogenesis, integrin-mediated extracellular matrix remodeling, and fibroblast activation, whereas growth hormone secretagogues like ipamorelin, CJC-1295, tesamorelin, sermorelin, and AOD-9604 activate IGF …

Authors
Rahman OF, Lee SJ, Seeds WA.
Source
peer_reviewed_research
DOI
10.5435/JAAOSGlobal-D-25-00236
PubMed
41490200
Open original source
2026Laboratory research
Evidence strength C · 63/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
72/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.

Marketed as more selective and ostensibly safer alternatives, peptides-including growth hormone secretagogues (e.g., Ipamorelin), growth hormone-releasing hormone analogues (e.g., CJC-1295, Sermorelin), and synthetic fragments (e.g., Frag 176-191, KPV)-are promoted for mus …

Authors
Coutinho LFD, DE Oliveira Neves LF, Camilo RP.
Source
peer_reviewed_research
DOI
10.23736/S0022-4707.26.17773-1
PubMed
41880199
Open original source
2020Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Attenuation of Visceral and Somatic Nociception by Ghrelin Mimetics.

Here, we investigate the efficacy of peripherally restricted (ipamorelin) and a globally active (HM01) selective ghrelin receptor agonist in an experimental model of non-inflammatory visceral hypersensitivity and somatic mechanical allodynia. ...RESULTS: Compared to vehicl …

Authors
N Mohammadi E, Louwies T, Pietra C, Northrup SR, Greenwood-Van Meerveld B.
Source
peer_reviewed_research
DOI
10.2147/JEP.S249747
PubMed
32801950
Open original source
2009Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.

In contrast, repetitive dosing of ipamorelin (0.1 or 1 mg/kg) significantly increased the cumulative fecal pellet output, food intake, and body weight gain. The results suggest that postsurgical intravenous infusions of ipamorelin may ameliorate the symptoms in pati …

Authors
Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B.
Source
peer_reviewed_research
DOI
10.1124/jpet.108.149211
PubMed
19289567
Open original source
2024Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus.

The objective of this study was to examine the impact of ipamorelin acetate (IPA), a ghrelin agonist, on the reproductive axis of the tilapia Oreochromis mossambicus. ...

Authors
Gouda M, Ganesh CB.
Source
peer_reviewed_research
DOI
10.1016/j.anireprosci.2024.107550
PubMed
38996787
Open original source
2026Laboratory research
Evidence strength C · 63/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
72/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.

Regenerative peptides (e.g., body protection compound-157 and thymosin derivatives) and growth hormone axis secretagogues (e.g., CJC-1295, ipamorelin, and tesamorelin) remain investigational, with uncertain safety profiles, product quality concerns, and widespread antidopi …

Authors
Villegas Meza AD, Nocek M, Mitchell BC, Lizarraga M, DeFoor MT, Ruzbarsky JJ, Huard J, Philippon MJ.
Source
peer_reviewed_research
DOI
10.2106/JBJS.RVW.26.00027
PubMed
42160466
Open original source
2026Laboratory research
Evidence strength D · 49/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
45/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.

The agents most commonly encountered in clinical practice and online self-administration protocols include growth hormone-releasing hormone (GHRH) analogues (e.g., sermorelin, tesamorelin, CJC-1295 with Drug Affinity Complex [DAC], CJC-1295 without DAC), growth hormone secretagog …

Authors
Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, RuchaŁa M.
Source
peer_reviewed_research
DOI
10.3389/fendo.2026.1822475
PubMed
42395176
Open original source
2012Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus.

The goal of this study was to investigate whether ipamorelin, a synthetic peptidomimetic that acts on the ghrelin receptor, accelerates gastric emptying in a rodent model of gastroparesis induced by abdominal surgery and intestinal manipulation. ...Following abdominal surg …

Authors
Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C.
Source
peer_reviewed_research
DOI
10.2147/JEP.S35396
PubMed
27186127
Open original source
2018Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Analysis of new growth promoting black market products.

Additionally, three analogues of GHRPs were identified as Gly-GHRP-6, Gly-GHRP-2 and Gly-Ipamorelin, representing the corresponding GHRP extended by a N-terminal glycine residue. The structure of these peptides was characterised by means of high resolution (tandem) mass sp …

Authors
Krug O, Thomas A, Malerød-Fjeld H, Dehnes Y, Laussmann T, Feldmann I, Sickmann A, Thevis M.
Source
peer_reviewed_research
DOI
10.1016/j.ghir.2018.05.001
PubMed
29864719
Open original source
2024Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.

This study investigated whether ghrelin mimetics, namely anamorelin and ipamorelin, can alleviate weight loss and inhibition of feeding observed during acute and delayed phases of cisplatin-induced emesis in ferrets. The potential of anamorelin to inhibit electrical field …

Authors
Lu Z, Ngan MP, Liu JYH, Yang L, Tu L, Chan SW, Giuliano C, Lovati E, Pietra C, Rudd JA.
Source
peer_reviewed_research
DOI
10.1016/j.physbeh.2024.114644
PubMed
39043357
Open original source
2020Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.

The GHS that will be discussed include sermorelin, growth hormone-releasing peptides (GHRP)-2, GHRP-6, ibutamoren, and ipamorelin. All are potent GH and IGF-1 stimulators that can significantly improve body composition while ameliorating specific hypogonadal symptoms inclu …

Authors
Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI.
Source
peer_reviewed_research
DOI
10.21037/tau.2019.11.30
PubMed
32257855
Open original source
2026Laboratory research
Evidence strength D · 49/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
45/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

This peer-reviewed source examines Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

Authors
Renke G, Chinellato L.
Source
peer_reviewed_research
DOI
10.3390/ijms27093890
PubMed
42123471
Open original source

Scientific context

Chemistry and represented biological context

Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.

Open chemistry and biological context ↓
Chemical identity

Molecular and structural record

Structured record
Molecular formula
C38H49N9O5
Molecular weight (Da)
711.86
Amino acid sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH2

Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.

Explore further

Continue through the research system

Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.

Research discovery

Compare peptides

Examine represented peptide records side by side.

Evidence system

Explore how scientific evidence is represented and reviewed.

Research hub

Enter the broader research and intelligence environment.

Methodology

Review project methods, boundaries, and interpretation rules.

Research

How the scientific record is developing

Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.

Research chronology

  1. 1998 · study · Temporal status not established

    Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption.

    peer_reviewed_research

  2. 1998 · study · Temporal status not established

    Ipamorelin, the first selective growth hormone secretagogue.

    peer_reviewed_research

  3. 1999 · study · Temporal status not established

    Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.

    peer_reviewed_research

  4. 1999 · study · Temporal status not established

    Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.

    peer_reviewed_research

  5. 2001 · study · Temporal status not established

    Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues.

    peer_reviewed_research

  6. 2001 · study · Temporal status not established

    The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.

    peer_reviewed_research

  7. 2002 · study · Temporal status not established

    Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro.

    peer_reviewed_research

  8. 2009 · study · Temporal status not established

    Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats.

    peer_reviewed_research

  9. 2009 · study · Temporal status not established

    Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.

    peer_reviewed_research

  10. 2012 · study · Temporal status not established

    Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus.

    peer_reviewed_research

  11. 2014 · study · Temporal status not established

    Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.

    peer_reviewed_research

  12. 2018 · study · Temporal status not established

    Analysis of new growth promoting black market products.

    peer_reviewed_research

  13. 2020 · study · Temporal status not established

    Attenuation of Visceral and Somatic Nociception by Ghrelin Mimetics.

    peer_reviewed_research

  14. 2020 · study · Temporal status not established

    Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.

    peer_reviewed_research

  15. 2024 · study · Temporal status not established

    The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus.

    peer_reviewed_research

  16. 2024 · study · Temporal status not established

    The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.

    peer_reviewed_research

  17. 2026 · study · Temporal status not established

    Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.

    peer_reviewed_research

  18. 2026 · study · Temporal status not established

    Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

    peer_reviewed_research

  19. 2026 · study · Temporal status not established

    Peptide Supplements and Their Therapeutic Applications in Sports Medicine.

    peer_reviewed_research

  20. 2026 · study · Temporal status not established

    Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

    peer_reviewed_research

  21. 2026 · study · Temporal status not established

    Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

    peer_reviewed_research

  22. 2026 · study · Temporal status not established

    A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.

    peer_reviewed_research

  23. 2026 · study · Temporal status not established

    Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.

    peer_reviewed_research

  24. 2026 · study · Temporal status not established

    The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.

    peer_reviewed_research

  25. 2026 · study · Temporal status not established

    Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

    peer_reviewed_research

  26. 2026 · regulatory · Temporal status not established

    Regulatory review: not_approved

    European Union (EMA)

  27. 2026 · regulatory · Temporal status not established

    Regulatory review: not_approved

    United States (FDA)

The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.

What still needs investigation

Claim traceability

No institutional claim record is currently represented for this peptide.

Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.

Researchers represented in the evidence record12 bibliographic identities · open to inspect

These are bibliographic author identities derived from represented records. Name strings are not proof of unique real-world researcher identity, and publishing organizations are not treated as institutional affiliations.

Johansen PB

4 represented evidence records

Years represented: 1998, 1999, 2001, 2009

Publishing organizations appearing in records: peer_reviewed_research

Greenwood-Van Meerveld B

3 represented evidence records

Years represented: 2009, 2012, 2020

Publishing organizations appearing in records: peer_reviewed_research

Pietra C

3 represented evidence records

Years represented: 2012, 2020, 2024

Publishing organizations appearing in records: peer_reviewed_research

Andreassen TT

2 represented evidence records

Years represented: 1999, 2001

Publishing organizations appearing in records: peer_reviewed_research

Greenwood-Van Meerveld B.

2 represented evidence records

Years represented: 2009, 2020

Publishing organizations appearing in records: peer_reviewed_research

Malmlöf K

2 represented evidence records

Years represented: 2001, 2009

Publishing organizations appearing in records: peer_reviewed_research

Mohammadi E

2 represented evidence records

Years represented: 2012, 2020

Publishing organizations appearing in records: peer_reviewed_research

Aagaard NK

1 represented evidence record

Years represented: 2009

Publishing organizations appearing in records: peer_reviewed_research

Agersø H

1 represented evidence record

Years represented: 1999

Publishing organizations appearing in records: peer_reviewed_research

Andersen JV

1 represented evidence record

Years represented: 1998

Publishing organizations appearing in records: peer_reviewed_research

Andersen NB

1 represented evidence record

Years represented: 2001

Publishing organizations appearing in records: peer_reviewed_research

Andersen PH.

1 represented evidence record

Years represented: 1998

Publishing organizations appearing in records: peer_reviewed_research

Connections

Follow the scientific relationships

Connections appear only when they are represented by the project’s underlying records.

Open 1 represented connection ↓

institution

peer_reviewed_research

represented evidence source

Traceability

Follow the record back to its source

The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.

Source publication state

A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.

Reviewer provenance state

“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.

Domain conclusion → Evidence

Connected

Evidence → Source

Connected

Source → Original record

Connected

Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.

Reconciled for 5 domain conclusions and 0 featured studies.

Detailed study-to-domain mappings and original-source paths appear in the Ipamorelin evidence-governance section.

Inspect the ranked source records

Observational archive

What contributors reported

Observational archive data is intentionally separated from published scientific evidence.

Observational boundary

Insufficient eligible observations are available for display under the current filters.

Insufficient eligible observations are currently represented to display aggregated findings for this peptide.

Regulatory context

Published jurisdictional records

Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.

Research + media

Media connected to this scientific record

Only media explicitly linked through the project’s relationship system appears here.

No scientifically connected media is currently represented for this peptide.

Sources + provenance

Read the scientific record with its boundaries intact

The public record organizes reviewed evidence; it does not establish scientific truth by itself.
Association, mechanism, observation and regulatory status must not be represented as proof of clinical efficacy or safety.
Observational reports describe contributor experiences and cannot establish causation, effectiveness, safety or clinical benefit.
Contradictory and qualifying evidence must remain visible rather than being silently discarded.
Absence of represented evidence is not evidence that research does not exist.
Research gaps identify unresolved questions; they are not negative conclusions.
Regulatory status is distinct from scientific evidence quality.
Media relationships provide context and explanation; they do not increase the strength of scientific evidence.
A section with no represented records is an incomplete project record, not a scientific conclusion.
Researcher and institutional relationships are shown only when supported by represented records and must not be interpreted as rankings or endorsements.

Generated: 11/8/2026, 5:28:45 PM

global evidence atlas

Ipamorelin research, ranked and separated by purpose

This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.

63Discoverable source universe
63Ranked screening records
5Research domains
0Accountably approved conclusions

63 matching records · ranked 2026-09-18

Page 1 of 3

Count reconciliation: 63 discoverable source records match the peptide identity query; 63 are retained in this bounded, ranked screening view; 0 belong to the separate governed layer labeled “Accountably approved conclusions.” Domain totals overlap because one publication may inform several questions.

governance and regulatory context

Ipamorelin: what this atlas does and does not establish

Last checked
2026-09-18
Accountable publication approval
Not yet approved by a named accountable reviewer. Machine screening only.

No new outcome conclusion is inferred from discovery metadata. Named accountable approval is required for governed scientific conclusions.

Regulatory status by jurisdiction

Absence of a record in this pass is not proof that no authorization exists. Status must remain jurisdiction-, product-, formulation-, and date-specific.

  • European Union (EMA)not approvedchecked 2026-09-08

    No centrally authorized EMA medicine for the named compound was identified in the EMA medicines database as of 8 September 2026.

    European Medicines Agency medicines database
  • United States (FDA)not approvedchecked 2026-09-08

    No FDA-approved drug product or therapeutic indication for the named compound was identified in Drugs@FDA as of 8 September 2026.

    Drugs@FDA: FDA-Approved Drugs

25 of 63 screening records carry a machine-proposed evidence-strength grade; the remainder are unassigned pending further review.

Ipamorelin evidence · ranking key

How evidence is ranked

A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.

A

Practice-defining evidence

Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.

B

Strong supporting evidence

Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.

C

Contextual evidence

Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.

D

Signal-generating evidence

Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.

Tier and confidence answer different questions

Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.

Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.

peptide explorer

Structural visualization and provenance

Evidence-class labeling remains visible even when interactive rendering is unavailable. Representative geometry is not an experimentally determined or predicted biological conformation.

Fully specified molecular identity

Molecular formula
C38H49N9O5
Molecular weight
711.9 g/mol
Exact identity / sequence notation
H-Aib-His-D-2-Nal-D-Phe-Lys-NH2
Identity-defining modifications
  • Aib1
  • D-2-naphthylalanine3
  • D-phenylalanine4
  • C-terminal amide
PubChem CID
9831659
InChIKey
NEHWBYHLYZGBNO-BVEPWEIPSA-N

Non-standard residues are retained in exact notation and rendered as X only in the schematic viewer.

Sources: NIH PubChem — Ipamorelin · reviewed 2026-09-17

Representative sequence-derived model
Structure source
Generated from this record's governed amino-acid sequence
Identifier
Not applicable — not a database structure
Method
Schematic layout ordered by residue position only; not a molecular-dynamics, homology, or fold prediction
Confidence / limitations
Illustrative only. Not physically accurate; carries no structural, binding-site, or activity meaning.
Provenance
WPF governed PeptideChemistry record
Retrieved / last reviewed
2026-09-17

This is a representative, sequence-derived model ordered by residue position only. It is not the peptide's experimentally determined or predicted biological conformation, and it carries no claim about real bond angles, distances, secondary structure, binding sites, or activity.

Suggested citation

  • APA

    World Peptide Foundation. (n.d.). Ipamorelin — Peptide Scientific Intelligence. World Peptide Foundation. (Updated September 8, 2026.) https://www.worldpeptidefoundation.org/directory/ipamorelin

  • AMA / Vancouver

    World Peptide Foundation. Ipamorelin — Peptide Scientific Intelligence. World Peptide Foundation website. Updated September 8, 2026. https://www.worldpeptidefoundation.org/directory/ipamorelin